ClinicalTrials.gg
CompletedNCT04109066CheckMate 7FLUpdated Jan 8, 2025Results posted

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

A Phase 3 interventional study of nivolumab and paclitaxel (PTX) in Breast Cancer, sponsored by Bristol-Myers Squibb. Completed at 240 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
521
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing nivolumab in Breast Neoplasms — 1 open to participants now, 8 under way, none of them phase 3. Nivolumab · Breast Neoplasms.

Enrollment
2nd of 22
521 · median 47
Started
2019
with 9 others
Phase 3
Only one
of the 22
Registered
22nd of 22
by date
Lead sponsor
2 of 22
Bristol-Myers Squibb

Among the 22 studies testing nivolumab in Breast Neoplasms, this one is the 2nd largest by enrollment, is one of 10 that started in 2019, is the only one in phase 3, and was the 22nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 22 studies testing nivolumab in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing nivolumab in Breast Neoplasms, or all of them as a file.
02

Study summary

A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer.

03

Conditions studied

  • Breast Cancer

Keywords

  • Nivolumab
  • Breast Cancer
  • Cancer
  • Estrogen Receptor-Positive (ER+)
  • Human Epidermal Growth Factor 2 Negative (HER2-)
  • Neoadjuvant
  • Adjuvant
  • Primary Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Localized invasive breast ductal carcinoma, confirmed by the local pathologist, that includes the following combined primary tumor and clinical node (cN) categories: T1c (tumor size = 2 cm)-T2 (tumor size > 2 cm), cN1-N2 OR T3-T4, cN0-cN2. Note: Axillary lymph node status must be assessed by fine needle or core biopsy.
  • Estrogen receptor-positive (ER+) breast cancer (BC) and with or without progesterone receptor (PgR) expression (determined on the most recently analyzed tissue sample, tested locally, and confirmed by the central laboratory), as defined in the relevant American Society of Clinical Oncology (ASCO)- College of American Pathologists (CAP) Guidelines.
  • Human epidermal growth factor receptor 2 (-) BC tested in the local laboratory, defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+, or 2+.
  • Tumor Grade 3 of ductal histology, Or Tumor Grade 2 of ductal histology having an ER expression level percentage between 1-10%
  • Must agree to provide primary breast tumor tissue at baseline and at surgery
  • Must be deemed eligible for surgery
  • Males and females must agree to follow specific methods of , if applicable, while participating in the trial
  • Must have an (ECOG) scale performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Breastfeeding, pregnant, or expecting to conceive or father children within the projected duration of the study, starting with the screening through 12 months for participants who receive cyclophosphamide, or 6 months for participants who do not receive cyclophosphamide, after the last dose of study treatment
  • Prior treatment with chemotherapy, endocrine therapy (ET), targeted therapy, and/or radiation therapy for the currently diagnosed breast cancer prior to enrollment
  • Prior treatment with an , anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Significant cardiovascular disease such as (LVEF) \< 50% at baseline as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan performed at screening, or Class III or IV myocardial disease as described by the
  • History of ipsilateral invasive BC, regardless of treatment, ipsilateral ductal carcinoma in situ treated with radiation, or contralateral invasive BC, at any time
  • Definitive clinical or radiologic evidence of disease
  • Multicentric BC (the presence of > 1 tumor in different quadrants of the breast)
  • Bilateral invasive BC

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
521 participants (actual)

Study arms

  • Experimental
    Arm A: Nivolumab combined with neoadjuvant CT and adjuvant ET

    Nivolumab with paclitaxel followed by nivolumab with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then nivolumab with adjuvant (post-surgery) endocrine therapy of investigator's choice

    Biological: nivolumab · Drug: paclitaxel (PTX) · Drug: anthracycline · Drug: cyclophosphamide · Drug: Endocrine Therapy · Procedure: Surgery

  • Placebo comparator
    Arm B: Placebo combined with neoadjuvant CT and then adjuvant ET

    Nivolumab placebo with paclitaxel followed by nivolumab placebo with anthracycline + cyclophosphamide as neoadjuvant (pre-surgery) treatment, then adjuvant (post-surgery) endocrine therapy of investigator's choice

    Drug: paclitaxel (PTX) · Other: nivolumab placebo · Drug: anthracycline · Drug: cyclophosphamide · Drug: Endocrine Therapy · Procedure: Surgery

Interventions

  • Biologicalnivolumab

    Specified Dose on Specified days

  • Specified dose on Specified days

  • Othernivolumab placebo

    Specified dose on Specified days

  • Specified dose on Specified days

  • Specified dose on Specified days

  • DrugEndocrine Therapy

    Variable endocrine therapy of investigators choice

  • ProcedureSurgery

    Surgery for breast cancer

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) Rate

    pCR rate is defined as the percentage of participants who achieved pCR. pCR is defined as no invasive residual disease in breast and lymph nodes performed by a local pathologist. Criteria for evaluation of pCR includes the following: pCR in breast, axillary lymph nodes and non-axillary sentinel node; no histologic evidence of invasive tumor cells; and pCR in the breast.

    Time frame: Up to approximately 37 months

Secondary outcomes

  1. Pathological Complete Response (pCR) Rate (PD-L1 >=1%)

    pCR rate is defined as the percentage of participants who achieved pCR. pCR is defined as no invasive residual disease in breast and lymph nodes performed by a local pathologist. Criteria for evaluation of pCR includes the following: pCR in breast, axillary lymph nodes and non-axillary sentinel node; no histologic evidence of invasive tumor cells; and pCR in the breast.

    Time frame: Up to approximately 37 months

  2. Number of Participants With Residual Cancer Burden (RCB)

    RCB is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. RCB is categorized into the following 4 classes: RCB-0: no residual disease; RCB-1: minimal residual disease; RCB-II: moderate residual disease; RCB-III: and extensive residual disease.

    Time frame: Up to approximately 37 months

  3. Number of Participants With Residual Cancer Burden (RCB) PD-L1 >=1%

    RCB is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. RCB is categorized into the following 4 classes: RCB-0: no residual disease; RCB-1: minimal residual disease; RCB-II: moderate residual disease; RCB-III: and extensive residual disease.

    Time frame: Up to approximately 37 months

  4. Number of Participants With Adverse Events (AEs)

    Number of participants with any grade adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relation with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From first dose to 30 days post last dose of neoadjuvant or adjuvant study therapy (Up to approximately 19 months)

  5. Number of Participants With Serious Adverse Events (SAEs)

    Number of participants with any grade serious adverse events (SAE). SAE is defined as any untoward medical occurrence that, at any dose: Results in death; is life threatening; requires inpatient hospitalization; results in persistent or significant disability; is a congenital anomaly/birth defect. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From first dose to 30 days post last dose of neoadjuvant or adjuvant study therapy (Up to approximately 19 months)

  6. Number of Participants Who Died

    Number of participants who died due to any cause.

    Time frame: Up to approximately 41 months

07

Results

Posted Mar 12, 2024

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneArm AArm B
Started263258
Completed260257
Not completed31
Withdrew: Participant withdrew consent20
Withdrew: Participant no longer meets study criteria11
Treatment
Participant flow — Treatment
MilestoneArm AArm B
Started260257
Received arm a treatment02
Completed167174
Not completed9383
Withdrew: Lack of efficacy24
Withdrew: Adverse event237
Withdrew: Participant request to discontinue study treatment1514
Withdrew: Withdrawal by subject88
Withdrew: Death30
Withdrew: Participant no longer meets study criteria22
Withdrew: Administrative reasons by sponsor23
Withdrew: Other reasons1723
Withdrew: Disease progression47
Withdrew: Study drug toxicity125
Withdrew: Adverse event unrelated to study drug10
Withdrew: Disease recurrence02
Withdrew: Not reported48

Outcome measures

PrimaryPathological Complete Response (pCR) Rate

pCR rate is defined as the percentage of participants who achieved pCR. pCR is defined as no invasive residual disease in breast and lymph nodes performed by a local pathologist. Criteria for evaluation of pCR includes the following: pCR in breast, axillary lymph nodes and non-axillary sentinel node; no histologic evidence of invasive tumor cells; and pCR in the breast.

Time frame:
Up to approximately 37 months
Reported as:
Number · Percentage of participants
Pathological Complete Response (pCR) Rate
Percentage of participantsArm AArm B
Pathological Complete Response (pCR) Rate24.5 (19.4 to 30.2)13.8 (9.8 to 18.7)
Statistical analysis
  • Arm A vs Arm B · Cochran-Mantel-Haenszel · p = 0.0021 · Odds ratio (or): 2.05 · 95% CI 1.29 to 3.27Stratified by PD-L1 by SP142 (\< 1% vs. \>= 1%), AC Dose-Frequency Chemotherapy Regimen (Q2W vs. Q3W) per IRT. Strata adjusted odds ratio (Arm A over Arm B) using Mantel-Haenszel method.
  • Arm A vs Arm B · Adjusted difference of pcr rates: 10.5 · 95% CI 4.0 to 16.9Strata adjusted difference in pCR (Arm A-B) based on Cochran-Mantel-Haenszel (CMH) method of weighting. Stratified by PD-L1 by SP142 (\< 1% vs. \>= 1%), AC Dose-Frequency Chemotherapy Regimen (Q2W vs. Q3W) per IRT.
SecondaryPathological Complete Response (pCR) Rate (PD-L1 >=1%)

pCR rate is defined as the percentage of participants who achieved pCR. pCR is defined as no invasive residual disease in breast and lymph nodes performed by a local pathologist. Criteria for evaluation of pCR includes the following: pCR in breast, axillary lymph nodes and non-axillary sentinel node; no histologic evidence of invasive tumor cells; and pCR in the breast.

Time frame:
Up to approximately 37 months
Reported as:
Number · Percentage of participants
Pathological Complete Response (pCR) Rate (PD-L1 >=1%)
Percentage of participantsArm AArm B
Pathological Complete Response (pCR) Rate (PD-L1 >=1%)44.3 (33.7 to 55.3)20.2 (12.3 to 30.4)
Statistical analysis
  • Arm A vs Arm B · Odds ratio (or): 3.11 · 95% CI 1.58 to 6.11Stratified by AC Dose-Frequency. Chemotherapy Regimen (Q2W vs. Q3W) per IRT. Strata adjusted odds ratio (Arm A over Arm B) using Mantel-Haenszel method.
  • Arm A vs Arm B · Adjusted difference of pcr rates: 24.1 · 95% CI 10.7 to 37.5Strata adjusted difference in pCR (Arm A-B) based on Cochran-Mantel-Haenszel (CMH) method of weighting. Stratified by AC Dose-Frequency Chemotherapy Regimen (Q2W vs. Q3W) per IRT.
SecondaryNumber of Participants With Residual Cancer Burden (RCB)

RCB is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. RCB is categorized into the following 4 classes: RCB-0: no residual disease; RCB-1: minimal residual disease; RCB-II: moderate residual disease; RCB-III: and extensive residual disease.

Time frame:
Up to approximately 37 months
Reported as:
Count of participants · Participants
Number of Participants With Residual Cancer Burden (RCB)
ParticipantsArm AArm B
RCB-06234
RCB-I1720
RCB-II90106
RCB-III5773
Not Reported3120
SecondaryNumber of Participants With Residual Cancer Burden (RCB) PD-L1 >=1%

RCB is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. RCB is categorized into the following 4 classes: RCB-0: no residual disease; RCB-1: minimal residual disease; RCB-II: moderate residual disease; RCB-III: and extensive residual disease.

Time frame:
Up to approximately 37 months
Reported as:
Count of participants · Participants
Number of Participants With Residual Cancer Burden (RCB) PD-L1 >=1%
ParticipantsArm AArm B
RCB-03816
RCB-I106
RCB-II2536
RCB-III920
Not Reported66
SecondaryNumber of Participants With Adverse Events (AEs)

Number of participants with any grade adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relation with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time frame:
From first dose to 30 days post last dose of neoadjuvant or adjuvant study therapy (Up to approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsArm AArm B
Adverse Events (AEs)259252
Drug-Related AEs254236
AEs leading to discontinuation4114
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

Number of participants with any grade serious adverse events (SAE). SAE is defined as any untoward medical occurrence that, at any dose: Results in death; is life threatening; requires inpatient hospitalization; results in persistent or significant disability; is a congenital anomaly/birth defect. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time frame:
From first dose to 30 days post last dose of neoadjuvant or adjuvant study therapy (Up to approximately 19 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsArm AArm B
Number of Participants With Serious Adverse Events (SAEs)8045
SecondaryNumber of Participants Who Died

Number of participants who died due to any cause.

Time frame:
Up to approximately 41 months
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsArm AArm B
Number of Participants Who Died158

Adverse events

Collected over Participants were assessed for all-cause mortality from their first dose to their study completion (up to approximately 41 months). SAEs and Other AEs were assessed from first dose up to 100 days post last dose (Up to approximately 21 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Nivo + Chemo (PTX QW + AC Q3W) / Nivo + ET8/129 (6.2%)38/127 (29.9%)126/127 (99.2%)
Arm A: Nivo + Chemo (PTX QW + AC Q2W) / Nivo + ET7/136 (5.1%)51/135 (37.8%)132/135 (97.8%)
Arm B: Nivo Placebo + Chemo (PTX QW + AC Q3W) / ET4/124 (3.2%)20/123 (16.3%)120/123 (97.6%)
Arm B: Nivo Placebo + Chemo (PTX QW + AC Q2W) / ET4/132 (3%)26/132 (19.7%)130/132 (98.5%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventArm A: Nivo + Chemo (PTX QW + AC Q3W) / Nivo + ETArm A: Nivo + Chemo (PTX QW + AC Q2W) / Nivo + ETArm B: Nivo Placebo + Chemo (PTX QW + AC Q3W) / ETArm B: Nivo Placebo + Chemo (PTX QW + AC Q2W) / ET
Febrile neutropeniaBlood and lymphatic system disorders3/1279/1350/1234/132
COVID-19Infections and infestations2/1275/1352/1231/132
PyrexiaGeneral disorders0/1274/1350/1230/132
COVID-19 pneumoniaInfections and infestations3/1271/1350/1230/132
PneumoniaInfections and infestations1/1273/1351/1233/132
NeutropeniaBlood and lymphatic system disorders2/1272/1352/1230/132
DiarrhoeaGastrointestinal disorders0/1270/1352/1230/132
AnaemiaBlood and lymphatic system disorders2/1272/1350/1230/132
Postoperative wound infectionInfections and infestations2/1271/1350/1230/132
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/1270/1350/1231/132
Most frequent other events
Showing 10 of 88
Most frequent other events
EventArm A: Nivo + Chemo (PTX QW + AC Q3W) / Nivo + ETArm A: Nivo + Chemo (PTX QW + AC Q2W) / Nivo + ETArm B: Nivo Placebo + Chemo (PTX QW + AC Q3W) / ETArm B: Nivo Placebo + Chemo (PTX QW + AC Q2W) / ET
AlopeciaSkin and subcutaneous tissue disorders83/12764/13580/12369/132
NauseaGastrointestinal disorders61/12777/13555/12359/132
FatigueGeneral disorders34/12767/13524/12352/132
AnaemiaBlood and lymphatic system disorders47/12765/13532/12362/132
DiarrhoeaGastrointestinal disorders30/12748/13526/12340/132
HeadacheNervous system disorders24/12743/13524/12333/132
ArthralgiaMusculoskeletal and connective tissue disorders21/12741/13520/12342/132
Neuropathy peripheralNervous system disorders26/12738/13519/12332/132
ConstipationGastrointestinal disorders23/12736/13519/12330/132
Aspartate aminotransferase increasedInvestigations32/12730/13523/12319/132

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm AArm BTotal
Mean49.9 ± 12.050.9 ± 11.850.4 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female262257519
Male112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm AArm BTotal
Hispanic or Latino7480154
Not Hispanic or Latino102121223
Unknown or Not Reported8757144
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm AArm BTotal
American Indian or Alaska Native181735
Asian241842
Native Hawaiian or Other Pacific Islander235
Black or African American6814
White202193395
More than one race000
Unknown or Not Reported111930
08

Study locations

240 sites
  • Local Institution - 0136
    Mobile, Alabama 36604, United States
  • Local Institution - 0052
    Greenbrae, California 94904, United States
  • Local Institution - 0051
    Whittier, California 90603, United States
  • Local Institution - 0182
    Stamford, Connecticut 06904, United States
  • Local Institution - 0150
    Jacksonville, Florida 32256, United States
  • Local Institution - 0097
    Miami, Florida 33136, United States
  • Local Institution - 0149
    Pensacola, Florida 32504, United States
  • Local Institution - 0120
    Tallahassee, Florida 32308, United States
  • Local Institution - 0054
    Athens, Georgia 30607, United States
  • Local Institution - 0107
    Atlanta, Georgia 30342, United States
  • Local Institution - 0056
    Columbus, Georgia 31904, United States
  • Local Institution - 0221
    Chicago, Illinois 60611, United States
  • Local Institution - 0227
    Fort Wayne, Indiana 46804, United States
  • Local Institution - 0222
    Topsham, Maine 04086, United States
  • Local Institution - 0146
    Bethesda, Maryland 20817, United States
  • HCA Midwest Division
    Kansas City, Missouri 64132, United States
  • Local Institution - 0109
    Florham Park, New Jersey 07932, United States
  • Local Institution - 0050
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0180
    New Brunswick, New Jersey 08903, United States
  • Local Institution - 0181
    Albuquerque, New Mexico 87131, United States
  • Local Institution - 0041
    Bronx, New York 10461, United States
  • Local Institution - 0283
    Charlotte, North Carolina 28204, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • Local Institution - 0053
    Cleveland, Ohio 44109, United States
  • Local Institution - 0218
    Nashville, Tennessee 37203, United States
  • Local Institution - 0121
    Fort Worth, Texas 76104, United States
  • Local Institution - 0224
    Fairfax, Virginia 22031, United States
  • Local Institution - 0122
    Fredericksburg, Virginia 22408, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
  • Local Institution - 0274
    Seattle, Washington 98109, United States
  • Local Institution - 0012
    Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
  • Local Institution - 0015
    La Plata, Buenos Aires 1900, Argentina
  • Local Institution - 0020
    Buenos Aires, Ciudad Autónoma De Buenos Aires C1417DTB, Argentina
  • Local Institution - 0294
    Córdoba, Cordoba X5000FHP, Argentina
  • Local Institution - 0303
    Río Cuarto, Cordoba 5800, Argentina
  • Local Institution - 0011
    Caba, Distrito Federal 1430, Argentina
  • Local Institution - 0008
    Capital Federal, Distrito Federal C1280AEB, Argentina
  • Local Institution - 0013
    Ciudad Autonoma de Buenos Aires, Distrito Federal 0, Argentina
  • Local Institution - 0014
    Rosario Santa Fe, Santa FE S2002KDS, Argentina
  • Local Institution - 0021
    Cordoba, X5000BAL, Argentina
  • Local Institution
    La Rioja, Argentina
  • Local Institution
    Viedma, Argentina
  • Local Institution - 0071
    North Sydney, New South Wales 2060, Australia
  • Local Institution - 0069
    Port Macquarie, New South Wales 2444, Australia
  • Local Institution - 0072
    Herston, Queensland 4029, Australia
  • Local Institution - 0067
    Elizabeth Vale, South Australia 5112, Australia
  • Local Institution - 0066
    Clayton, Victoria 3168, Australia
  • Local Institution - 0142
    Clayton, Victoria 3168, Australia
  • Local Institution - 0070
    Melbourne, Victoria 3000, Australia
  • Local Institution - 0068
    North Ballarat, Victoria 33500, Australia
  • Local Institution - 0045
    Graz, 8036, Austria
  • Local Institution - 0042
    Innsbruck, 6020, Austria
  • Local Institution - 0048
    Salzburg, 5020, Austria
  • Local Institution - 0046
    Wien, 1090, Austria
  • Local Institution - 0047
    Wien, 1090, Austria
  • Local Institution - 0187
    Brussels, 1090, Belgium
  • Local Institution - 0030
    Charleroi, 6000, Belgium
  • Local Institution - 0037
    Edegem, 2650, Belgium
  • Local Institution - 0032
    Gent, 9000, Belgium
  • Local Institution - 0031
    Liege, 4000, Belgium
  • Local Institution - 0130
    Fortaleza, Ceara 60135-237, Brazil
  • Local Institution - 0225
    Brasilia, Distrito Federal 70200-730, Brazil
  • Local Institution - 0287
    Goiânia, Goias 74605070, Brazil
  • Local Institution - 0133
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Local Institution - 0132
    Ijui, RIO Grande DO SUL 98700-000, Brazil
  • Local Institution - 0288
    Porto Alegre, RIO Grande DO SUL 90035-001, Brazil
  • Local Institution - 0131
    Porto Alegre, Rio Grande Do Sul 90050-170, Brazil
  • Local Institution - 0135
    Porto Alegre, RIO Grande DO SUL 90610-000, Brazil
  • Local Institution - 0273
    Santa Cruz do Sul, Rio Grande Do Sul 96830-180, Brazil
  • Local Institution - 0134
    Barretos, SAO Paulo 14784-400, Brazil
  • Local Institution - 0272
    São Paulo, SAO Paulo 01229-010, Brazil
  • Local Institution - 0128
    Santo André, São Paulo 09060-870, Brazil
  • Local Institution - 0129
    Rio de Janeiro, 22793-080, Brazil
  • Local Institution - 0144
    São Paulo, 01317-000, Brazil
  • Local Institution - 0104
    São Paulo, 04378-500, Brazil
  • Local Institution - 0194
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0095
    Montréal, Quebec H2X 0C1, Canada
  • Local Institution - 0058
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution - 0197
    La Serena, Coquimbo 1720430, Chile
  • Local Institution - 0016
    Santiago de Chile, Metropolitana 0, Chile
  • Local Institution - 0019
    Santiago Region Metropolitana, Metropolitana 8330034, Chile
  • Local Institution - 0318
    Santiago, Metropolitana 6900941, Chile
  • Local Institution - 0018
    Vina del Mar, Valparaiso 2520598, Chile
  • Local Institution - 0326
    Antofagasta, Chile
  • Local Institution - 0235
    Bengbu, Anhui 233004, China
  • Local Institution - 0239
    Hefei, Anhui 230031, China
  • Local Institution
    Beijing, Beijing 100021, China
  • Local Institution - 0319
    Chongqing, Chongqing 400016, China
  • Local Institution - 0232
    Chongqing, Chongqing 400030, China
  • Local Institution - 0267
    Guangzhou, Guangdong 510060, China
  • Local Institution - 0241
    Guangzhou, Guangdong 510080, China
  • Local Institution
    Guangzhou, Guangdong 510515, China
  • Local Institution - 0312
    Zunyi, Guizhou 563000, China
  • Local Institution - 0240
    Shjiazhuang, Hebei 50051, China
  • Local Institution - 0250
    Wuhan, Hebei 430022, China
  • Local Institution - 0248
    Harbin, Heilongjiang 150001, China
  • Local Institution
    Zhengzhou, Henan, China
  • Local Institution - 0255
    Changchun, Jilin 130012, China
  • Local Institution - 0247
    Changchun, Jilin 130021, China
  • Local Institution - 0252
    Shenyang, Liaoning 110042, China

Showing the first 100 of 240 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jan 2023, 37 months.

Results were first posted in Mar 2024, 1 year 1 month after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 37 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2019
First posted
Sep 30, 2019
StartActual
Nov 18, 2019
Primary completionActual
Jan 16, 2023
CompletionActual
Dec 27, 2023
Results first posted
Mar 12, 2024
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04109066
Responsible party
Sponsor
First posted
Sep 30, 2019
Start date
Nov 18, 2019
Primary completion
Jan 16, 2023
Completion
Dec 27, 2023
Results posted
Mar 12, 2024
Last update
Jan 8, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion